Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy. What is known?;Frischplasma und faktorenkonzentrate zur therapie der perioperativen koagulopathie. Was ist bekannt?

Anaesthesist

Volumn 55, Issue 9, 2006, Pages 926-936

  Heindl, B ^a   Spannagl, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coagulopathy; Dosage; Hemotherapy; Safety; Side effect

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOGEN; FRESH FROZEN PLASMA; PROCOAGULANT; PROTEIN C; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR;

ALLERGIC REACTION; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW; GERMANY; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION; LIVER FUNCTION; PERIOPERATIVE PERIOD; PLASMA HALF LIFE; PLASMA TRANSFUSION; PRACTICE GUIDELINE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; VIRUS INACTIVATION;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; HEMOSTATIC TECHNIQUES; HUMANS; INTRAOPERATIVE COMPLICATIONS; PERIOPERATIVE CARE; PLASMA; POSTOPERATIVE COMPLICATIONS;

EID: 33748806820     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-006-1038-z     Document Type: Article

References (46)

1. Barletta JF, Ahrens CL, Tyburski JG et al. (2005) A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 58: 646-651
2. Boffard KD, Riou B, Warren B et al. (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59: 8-15
3. Brohi K, Singh J, Heron M et al. (2003) Acute traumatic coagulopathy. J Trauma 54: 1127-1130
4. Bundesärztekammer (2005) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzte-Verlag, Köln
5. Cartmill M, Dolan G, Byrne JL et al. (2000) Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 14: 458-461
6. Chowdhury P, Saayman AG, Paulus U et al. (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 125: 69-73
7. Deutsches Rotes Kreuz (2004) Humanes S/D-Plasma, lyophilisert - Das virusinaktivierte Human-plasma der DRK-Blutspendedienste West gGMBH. Haemotherapie 2: R1-R8
8. Domen RE, Hoeltge GA (2003) Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 127: 316-320
9. Foster PR, Welch AG, McLean C et al. (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 78: 86-95
10. Fries D, Haas T, Salchner V et al. (2005) Gerinnungsmanagement beim Polytrauma. Anaesthesist 54: 137-144
11. Gerlach R, Tolle F, Raabe A et al. (2002) Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 33: 1618-1623
12. Gilstad CW, Ketchum LH, Hmel PJ et al. (2002) Lack of PF3 activity in solvent/detergent treated plasma. Vox Sang [Suppl 2]: 223-224
13. Gödje O, Haushofer M, Lamm P et al. (1998) The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 46: 263-267
14. Grundmann C, Plesker R, Kusch M et al. (2005) Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence. Thromb Haemost 94: 1338-1339
15. Hardy JF, Moerloose P de, Samama M (2004) Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 51: 293-310
16. Haschberger B, Waterkamp A, Heiden M et al. (2005) Bericht zur Meldung nach §21 TFG für die Jahre 2001 und 2002. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48: 99-119
17. Heiden M, Seitz R (2002) Quality of therapeutic plasma-requirements for marketing authorization. Thromb Res 107 [Suppl 1]: S47-51
18. Heindl B, Delorenzo C, Spannagl M (2005) Hochdosierte Fibrinogengabe zur Akuttherapie von Gerinnungsstörungen bei perioperativer Massivtransfusion. Anaesthesist 54: 787-790
19. Hellstern P (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11: 346-350
20. Hellstern P, Muntean W, Schramm W et al. (2002) Practical guidelines for the clinical use of plasma. Thromb Res 107 [Suppl 1]: S53-57
21. Hiippala ST, Myllyla GJ, Vahtera EM (1995) Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 81: 360-365
22. Innerhofer P, Fries D, Margreiter J et al. (2002) The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 95: 858-865
23. Ironside JW, Head MW (2004) Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 10 [Suppl 4]: 64-69
24. Jonge J de, Groenland TH, Metselaar HJ et al. (2002) Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 94: 1127-1131
25. Joshi GP (2005) Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. Anesth Analg 101: 601-605
26. Köhler M (1999) Thrombogenicity of prothrombin complex concentrates. Thromb Res 95: S13-17
27. Llewelyn CA, Hewitt PE, Knight RS et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: 417-421
28. Martinowitz U, Michaelson M (2005) Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3: 640-648
29. Nomura S, Okamae F, Abe M et al. (2000) Platelets expressing P-selectin and platelet-derived microparticles in stored platelet concentrates bind to PSGL-1 on filtrated leukocytes. Clin Appl Thromb Hemost 6: 213-221
30. O'Shaughnessy DF, Atterbury C, Bolton Maggs P et al. (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126: 11-28
31. Peden AH, Head MW, Ritchie DL et al. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: 527-529
32. Popovsky MA, Moore SB (1985) Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25: 573-577
33. Roth WK, Seifried E (2003) Infektionsrisiken durch Blutkomponenten und Blutprodukte. Hämotherapie 1: 22-35
34. Schreiber GB, Busch MP, Kleinman SH et al. (1996) The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334: 1685-1690
35. Scott VL, Wolf AM de, Kang Y et al. (1996) Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication. Liver Transpl Surg 2: 343-347
36. Soucie JM, Robertson BH, Bell BP et al. (1998) Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 38: 573-579
37. Spahn DR, Rossaint R (2005) Coagulopathy and blood component transfusion in trauma. Br J Anaesth 95: 130-139
38. Stanworth SJ, Brunskill SJ, Hyde CJ et al. (2004) Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126: 139-152
39. Staudinger T, Frass M, Rintelen C et al. (1999) Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 25: 1105-1110
40. Tabor E (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168
41. Toy P, Popovsky MA, Abraham E et al. (2005) Transfusion-related acute lung injury: definition and review. Crit Care Med 33: 721-726
42. Wallis JP, Lubenko A, Wells AW et al. (2003) Single hospital experience of TRALI. Transfusion 43: 1053-1059
43. Yarranton H, Cohen H, Pavord SR et al. (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121: 778-785
44. Yasaka M, Sakata T, Naritomi H et al. (2005) Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 115: 455-459
45. Yee TT, Cohen BJ, Pasi KJ et al. (1996) Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 93: 457-459
46. Youssef WI, Salazar F, Dasarathy S et al. (2003) Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 98: 1391-1394